Evaluation of the gut microbiota in patients with type 2 Diabetes mellitus using Semaglutide

niversidade Estadual de Campinas0 个研究点开始时间: 2024年8月9日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Both sexes; aged between 18-60 years; individuals with type 2 Diabetes Mellitus or Pre-Diabetes; with glycated hemoglobin between 5,7% and 10%; body mass index (BMI) of 25-39.99 Kg/m²; not using medication for Diabetes or using only oral antidiabetics (metformin and/or sulfonylurea); and creatinine clearance above 30ml/min/1,73m²

•Age outside the proposed range; pregnant women; smoking; patients with Type 1 Diabetes Mellitus; individuals with suspected or confirmed retinopathy; patients with chronic intestinal pathology; patients previously submitted to bariatric surgery or any surgery that results in any one of resection/injury of the nervous plexus/deviation of intestinal transit; patients with severe chronic kidney disease (creatinine clearance = 30ml/min/1.73m²); patients with moderate-intense gastroesophageal reflux disease; patients with a history of recurrent pancreatitis (because of an unclear cause, or an identified and still present cause); individuals who are using insulin; individuals who used any type of antibiotic in the last 3 months; individuals who make continuous use of probiotic drugs or proton pump inhibitors (omeprazole, pantoprazole, lansoprazole, esomeprazole, etc.); individuals who have used GLP-1 analogue drugs in the last 3 months; individuals who have a significant psychiatric disorder that may be related to the incorrect use of the medication and interfere with the results (schizophrenia, bipolar disorder, alcoholism, use of illicit substances, etc)

发起方

niversidade Estadual de Campinas